Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Details)

v3.20.1
Earnings (Loss) Per Common Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Basic and diluted numerator:        
Net loss attributable to iBio, Inc. $ (4,676) $ (4,223) $ (12,901) $ (13,090)
Deemed dividends - down round of Series A Preferred and Series B Preferred 0 0 (21,560) 0
Preferred stock dividends - iBio CMO Preferred Tracking Stock (65) (64) (196) (195)
Net loss available to iBio, Inc. stockholders $ (4,741) $ (4,287) $ (34,657) $ (13,285)
Basic and diluted denominator:        
Weighted-average common shares outstanding 79,917 19,224 47,018 18,597
Per share amount $ (0.06) $ (0.22) $ (0.74) $ (0.71)